Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ruxolitinib phosphate, quantity: 6.6 mg (equivalent: ruxolitinib, qty 5 mg) - tablet - excipient ingredients: hyprolose; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate type a - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.,jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.,jakavi is indicated for the treatment of patients aged 12 years and older with acute graft-versus-host disease who have inadequate response to corticosteroids.,jakavi is indicated for the treatment of patients aged 12 years and older with chronic graft-versus-host disease who have inadequate response to corticosteroids.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ruxolitinib phosphate, quantity: 26.4 mg (equivalent: ruxolitinib, qty 20 mg) - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; hyprolose; magnesium stearate; lactose monohydrate; sodium starch glycollate type a; povidone - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.,jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.,jakavi is indicated for the treatment of patients aged 12 years and older with acute graft-versus-host disease who have inadequate response to corticosteroids.,jakavi is indicated for the treatment of patients aged 12 years and older with chronic graft-versus-host disease who have inadequate response to corticosteroids.

Australia - English - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 125 mg; lumacaftor, quantity: 100 mg - tablet, film coated - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; microcrystalline cellulose; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; purified water; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350; cochineal; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Australia - English - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 75 mg; ivacaftor, quantity: 94 mg - granules - excipient ingredients: croscarmellose sodium; hypromellose acetate succinate; microcrystalline cellulose; povidone; sodium lauryl sulfate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

4 farmers australia pty ltd - triclopyr present as the butoxyethyl ester - emulsifiable concentrate - triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 600.0 g/l - herbicide - commercial area - general | fallow crop land weed control | fire trail | firebreak weed control | forest | industrial land or ar - acacia genus | african boxthorn | angophora | australian or native blackthorn | banksia | bitter bark or quinine tree | black or brisbane black wattle | blackberry | brigalow | broadleaf hopbush | brooms | brown salwood or hickory wattle | budda or false sandalwood | camel or afghan melon | camphor laurel - seedling | capeweed | castor oil bush | chilean cestrum | chinee apple | common prickly pear | dawson gum | english broom | english ivy | eucalyptus - seedling and sucker | eucalyptus species - see label | fennel | furze or gorse | green or early black wattle | groundsel bush | groundsel bush - seedling | horehound | lantana - lantana camara | narrow leaf hop bush | needlewood | olive - olea europaea | paddy melon | paperbark | prickly acacia | privet | rubber vine | saffron thistle | silver wattle | smooth tree or drooping prickly pear | st john's wort | sweet briar or wild rose | tiger pear | tree-of-heaven | turpentine bush | yellow wood | afghan melon | bitter melon | black wattle | blackberry with st

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

coromandel australia pty ltd - triclopyr present as the butoxyethyl ester - emulsifiable concentrate - triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 600.0 g/l - herbicide - agricultural non-crop areas | commercial/industrial land | fallow land | fenceline weed control | fire trail | firebreak weed co - acacia genus | african boxthorn | angophora - regrowth | australian or native blackthorn | banksia - regrowth | bitter bark or quinine tree | blackberry | blackberry in assoc with other weed (see | brigalow | broadleaf hopbush | brooms | brown salwood or hickory wattle | budda or false sandalwood | camel or afghan melon | camphor laurel | capeweed | castor oil bush | chilean cestrum | chinee apple | common prickly pear | dawson gum | english broom | english ivy | eucalyptus | eucalyptus - see label for exceptions | eucalyptus - seedling and sucker | fennel | furze or gorse | green or early black wattle | groundsel bush | horehound | lantana - lantana camara | narrow leaf hop bush | needlewood | olive - olea europaea | paddy melon | paperbark | prickly acacia | privet | rubber vine | saffron thistle | silver wattle | smooth tree or drooping prickly pear | sweet briar or wild rose | tiger pear | tree-of-heaven | turpentine bush | yellow wood | afghan melon | bitter melon | black wattle | blackberry with dock |

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pharmachem australia pty ltd - lanolin; iodine; pine oil; turpentine oil - topical cream, ointment, paste, gel, lotion - lanolin extract-animal active 22.5 g/l; iodine mineral-iodine active 2.0 g/l; pine oil oil-plant extract active 134.0 g/l; turpentine oil oil-plant extract active 333.0 g/l - dermatological preps. - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - keratolytic or cleaning agent | biotin deficiency | brittle hoof | cleansing agents | coat appearance | conditioning | conjunctivitis | cracked hoof | dry skin | flaking | galls | grooming aids | hoof conditioning | hoof moisturising | hopple chafes | itching | laminitis | moisturising | pliability | psoriasis | scratches | skin cleanser | wart removal

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - tenofovir alafenamide fumarate, quantity: 11.2 mg; emtricitabine, quantity: 200 mg; elvitegravir, quantity: 150 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; microcrystalline cellulose; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - genvoya is indicated as a single tablet regimen for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are either treatment?na?ve; or virologically suppressed (hiv-1 rna <50 copies/ml) on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see 5.1 pharmacodynamic properties, clinical trials). patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of genvoya. genvoya is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - methylprednisolone, quantity: 4 mg - tablet - excipient ingredients: gelatin; maize starch; magnesium stearate; purified talc; lactose monohydrate - yonsa mpred is indicated for the treatment of patients with: newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or; patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or; patients with mcrpc who have received prior chemotherapy containing a taxane.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - abiraterone acetate, quantity: 250 mg - tablet - excipient ingredients: colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; povidone - zytiga is indicated in combination with prednisone or prednisolone for the treatment of: ? newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or ? patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or ? patients with mcrpc who have received prior chemotherapy containing a taxane.